ACC CardiaCast

Echocardiography (Echo) and point-of-care ultrasound (POCUS) play a critical role in the cardiac intensive Care Unit (CICU). In this episode, our expert cardiologists Drs. Rosy Thachil, Shashank Sinha, Smadar Kort and Eugene Yuriditsky examine the latest advancements, techniques, and clinical applications of Echo and POCUS in managing critically ill cardiac patients. Learn how these powerful imaging tools can enhance diagnostic accuracy, provide real-time data, guide therapeutic interventions, and improve patient outcomes in the high-stakes environment of the CICU. Whether you're a seasoned cardiologist or a healthcare professional new to critical care cardiology, there is much to learn from these valuable insights and practical tips for optimizing the use of Echo and POCUS.  Related References:  Kirkpatrick JN, Grimm R, Johri AM, et al. Recommendations for echocardiography laboratories participating in cardiac point of care cardiac ultrasound (POCUS) and critical care echocardiography training: report from the American Society of Echocardiography.  J Am Soc Echocardiogr 2020;33:409-422.e4.   Subscribe to CardiaCast |  

Special Edition: PharmD Appreciation: “PulseCheck” is a series within CardiaCast that is designed for Cardiovascular (CV) Team members who are new, or new to cardiology, offering practical team-based solutions to the everyday challenges. This series, published during American Pharmacists Month, celebrates our pharmacist CV Team members in an educational series with a specific Pharmacist focus. In this episode, Andrea Price, MS, AACC hosts Tomasz Jurga, PharmD, BCPS, BCACP, BCCP, HF-Cert, AACC; Lydia Tran, PharmD, BCPS and Bruce Warden, PharmD, BCPS, FNLA, FASPC to discuss the role of the pharmacists of the care team for lipid management.     Subscribe to CardiaCast  

Special Edition: PharmD Appreciation: “PulseCheck” is a series within CardiaCast that is designed for Cardiovascular (CV) Team members who are new, or new to cardiology, offering practical team-based solutions to the everyday challenges. This series, published during American Pharmacists Month, celebrates our pharmacist CV Team members in an educational series with a specific Pharmacist focus. In this episode, Andrea Price, MS, AACC hosts Lydia Tran, PharmD, BCPS and Sushma Dey, PharmD, BCACP to discuss the role of the pharmacists on the care team for hypertension management.      Subscribe to CardiaCast  

In this installment of Atrial Fibrillation (AFib) and Antiarrhythmic Drugs (AADs) series, Dr. Suneet Mittal interviews Dr. Jeff Healey about evidence supporting the guidelines and how they compare to previous guidelines. Listen as Dr. Healey analyzes the utilization of AADs based on the 2023 guidelines.  This podcast is part of Early Onset of Atrial Fibrillation & the Contemporary Use of Antiarrhythmic Drugs grant initiative.    Educational grant support is provided by Sanofi. Click here for more: https://learn.acc.org/Page/LearnAntiarrhythmicDrugsforAF     Subscribe to CardiaCast | Claim CME Credit 

Special Edition: PharmD Appreciation: “PulseCheck” is a series within CardiaCast that is designed for Cardiovascular (CV) Team members are new, or new to cardiology, offering practical team-based solutions to the everyday challenges. This series, published during American Pharmacists Month, celebrates our pharmacist CV Team members in an educational series with a specific Pharmacist focus. In this episode, Andrea Price, MS, AACC hosts Anastasia Armbruster, PharmD, FACC, BCCP and Megan Labreck, PharmD, BCPS, CACP to discuss the most recent atrial fibrillation (Afib) guidelines and what the documents mean to a pharmacist working on a cardiac arrhythmia care team.   Subscribe to CardiaCast  

In this episode of CardiaCast, hypertrophic cardiomyopathy (HCM) expert Dr. Matthew Martinez will discuss with Dr. Michelle Kittleson recommendations for early diagnosis in the 2024 HCM guideline and review the latest clinical and real-world trial data for new (mavacamten) and emerging (aficamten) cardiac myosin inhibitors.   This CardiaCast is part of an educational series, “2024 Update to the AHA/ACC HCM Guideline: Expert Interpretation for Application to Practice,” which includes a total of three ACC CardiaCasts and an accredited #MedX. The series is produced by the American College of Cardiology Foundation and Med-IQ and supported by an educational grant from Bristol Myers Squibb. Exploring HCM Diagnosis and Treatment Options: The New Frontier of Cardiac Myosin Inhibitors (acc.org)   Suggested Materials:    Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;396:759-69. Erratum in: Lancet 2020;396:758.   Desai MY, Owens A, Wolski K, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol 2023;8:968-77.   Maron MS, Masri A, Nassif ME, et al; SEQUOIA-HCM Investigators. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 2024;390:1849-61.  

Special Edition: PharmD Appreciation: “PulseCheck” is a series within CardiaCast that is designed for Cardiovascular (CV) Team members who are new, or new to cardiology, offering practical team-based solutions to everyday challenges. This series, published during American Pharmacists Month, celebrates our pharmacist CV Team members in an educational series with a specific PharmD focus. In this episode, Andrea Price, MS, AACC hosts Jessie Dunne, PharmD, BCCP, BCPC and Orly Vardeny, PharmD, MS, FAHA, FHFSA to discuss the most recent heart failure guidelines, expert consensus publication, and what these documents mean to a pharmacist working on a heart failure care team.    Subscribe to CardiaCast  

In this episode of CardiaCast, hypertrophic cardiomyopathy (HCM) expert Dr. Matthew Martinez will discuss with Dr. Cesar Herrera challenges that exist in Latin America related to the application of the recently issued guideline, “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.”     This CardiaCast is part of an educational series, “2024 Update to the AHA/ACC HCM Guideline: Expert Interpretation for Application to Practice,” which includes a total of three ACC CardiaCasts and an accredited #MedX. The series is produced by the American College of Cardiology Foundation and Med-IQ and supported by an educational grant from Bristol Myers Squibb. Exploring HCM Diagnosis and Treatment Options: The New Frontier of Cardiac Myosin Inhibitors (acc.org)  Subscribe to CardiaCast  

“PulseCheck” is a series within CardiaCast that is designed for nurses or allied healthcare professionals who are new, or new to cardiology, offering practical team-based solutions to the challenges that nurses and allied health professionals face every day. This series, published during Peripheral Artery Disease (PAD) Awareness Month, is in collaboration with the ACC’s Vascular Disease Section. In this episode, Andrea Price, MS, AACC hosts Demetria Bolden, PhD, MBA, CPTD, Osama Ibrahim, MD, FACC and Bailey Estes, MSN, AGNP-C for the final installment of the PAD series focused on the impact of social determinants of health for the PAD patient population.   Subscribe to CardiaCast  

“PulseCheck” is a series within CardiaCast that is designed for nurses or allied healthcare professionals who are new, or new to cardiology, offering practical team-based solutions to the challenges that nurses and allied health professionals face every day. This series, published during Peripheral Artery Disease (PAD) Awareness Month, is in collaboration with the ACC’s Vascular Disease Section. In this episode, Andrea Price, MS, AACC hosts Craig Beavers, BCCP, BCPS-AQ, FACC, Maya Serhal MD, FACC and Bailey Estes MSN, AGNP-C for a discussion on guideline directed medical therapy (GDMT) and supervised exercise therapy in the treatment of PAD.    Subscribe to CardiaCast  

 “PulseCheck” is a series within CardiaCast that is designed for nurses or allied healthcare professionals who are new, or new to cardiology, offering practical team-based solutions to the challenges that nurses and allied health professionals face every day. This series, published during Peripheral Artery Disease (PAD) Awareness Month, is in collaboration with the ACC’s Vascular Disease Section. In this episode, Andrea Price, MS, AACC hosts Derek Pineda, NP, AACC, Bailey Estes, MSN, AGNP-C, and Pradeep Nair, MD, FACC for a discussion of interventional treatment options for PAD.    Subscribe to CardiaCast  

PulseCheck” is a series within CardiaCast that is designed for nurses or allied healthcare professionals who are new, or new to cardiology, offering practical team-based solutions to the challenges that nurses and allied health professionals face every day. This series, published during Peripheral Artery Disease (PAD) Awareness Month, is in collaboration with the ACC’s Vascular Disease Section. In this episode, Andrea Price, MS, AACC hosts Hussein Abu Daya MD, FACC, Brian Rose, PA-C, MPH, AACC and Bailey Estes MSN, AGNP-C, to begin the PAD series with an introductory overview.  

“Courtside with the Chair” is a new series within CardiaCast presented by the Sports and Exercise Cardiology Member Section covering topics within the field of sports and exercise cardiology. In this “Part 2” episode, Dr. Jonathan Kim continues the conversation with Drs. Michael Ackerman, Rachel Lampert, and Matthew Martinez of the “how to” and approach to shared decision-making in the context of sports participation for athletes with heart disease.  Suggested Materials: (You can include formal references external to ACC.org here. Please list numerically as formal citations. Example: Cannon JA, Moffitt P, Perez-Moreno AC, et al. Cognitive impairment and heart failure: systematic review and meta-analysis. J Card Fail 2017;23:464-75).       Subscribe to CardiaCast | Claim CME Credit 

In this episode, Drs. Erin Michos and Steven Nissen discuss newly emerging therapies for elevated Lp(a) management and forthcoming developments in research. Drs. Michos and Nissen highlight the key differences between therapies in late trial stages and discuss upcoming cardiovascular outcome trials.    This CardiaCast episode is part of an ACC course titled Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap. Educational grant support is provided by Novartis. To visit the Online Course page for the Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap Grant, click here!   Suggested Materials:   Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): actionable strategies for risk assessment and mitigation. Am J Prev Cardiol. 2024;18:100651.   Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018;71:177-92.    Reyes-Soffer G, Ginsberg HN, Berglund L, et al; on behalf of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. ArteriosclerThromband Vasc Biol 2022;42:e48-e60.    Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol 2024;18:e308-e319.   Subscribe to CardiaCast | More information on Elevating Lp(a) HERE 

“Courtside with the Chair” is a new series within CardiaCast presented by the Sports and Exercise Cardiology Member Section covering topics within the field of sports and exercise cardiology. In this episode, Dr. Jonathan Kim is joined by Drs. Michael Ackerman, Rachel Lampert, and Matthew Martinez to discuss the “why” and “how to” related to shared decision-making in the context of sports participation for athletes with heart disease.   Subscribe to CardiaCast | Claim CME Credit 

“PulseCheck” is a series within CardiaCast that is designed for nurses or allied healthcare professionals who are new, or new to cardiology, offering practical team-based solutions to the challenges that nurses and allied health professionals face every day. This episode is an update to the March 2024 PulseCheck: Shared Decision Making podcast in which host Andrea Price MS, AACC brings together Liz Perpetua ARNP, ACNP-BC, DNP, FACC, Martha Gulati MD, MS, FACC, and Bailey Estes MSN, AGNP-C, to explore best practices related to structural heart disease. Dr. Perpetua, the chair and lead author of JACC Advances Expert Panel Perspective: Shared Decision-Making in Multidisciplinary Team-Based Cardiovascular Care, offers insights from the July 2024 publication.    Subscribe on iTunes | Subscribe on Google Play |  

In this episode, Drs. Erin Michos and Gissette Reyes-Soffer discuss how clinicians can manage elevated Lp(a) by treating all modifiable factors in patients. The global risk assessment of patients and what can be done now to navigate and mitigate risk is also addressed.   This CardiaCast episode is part of an ACC course titled Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap. Educational grant support is provided by Novartis. To visit the Online Course page for the Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap Grant, click here!   Suggested Materials:   Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): actionable strategies for risk assessment and mitigation. Am J Prev Cardiol 2024;18:100651.    Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018;71:177-92.    Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al; on behalf of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2022;42:e48-e60.   Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol 2024;Mar 29:[ePub ahead of print].   Subscribe to CardiaCast | More information on Elevating Lp(a) HERE 

In this episode, Drs. Erin Michos and Christie Ballantyne examine the importance of testing and identifying lipoprotein(a) ( Lp[a]) levels in patients, research highlighting trends in populations at risk, and the genetic factors involved in assessment. The significance associated with various levels of Lp(a) in measurement and how testing plays a role in management is also discussed.  This CardiaCast episode is part of an ACC course titled Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap. Educational grant support is provided by Novartis. To visit the Online Course page for the Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap Grant, click here! 

In this episode, Drs. Maya Guglin, Nikhil Narang, Dustin Hillerson, Anju Bhardwaj, and Megan Pelter will delve into recently published randomized controlled clinical trials on venoarterial extracorporeal membrane oxygenation (VA-ECMO). They will cover trials on cardiogenic shock, including the ECMO-CS multicenter randomized trial, and discuss findings from the EVOLVE-ECMO trial on left ventricular venting. 

In this episode of CardiaCast, world-renowned hypertrophic cardiomyopathy (HCM) expert Dr. Matthew Martinez will review changes occurring in the field of HCM and explore best practice recommendations from the newly issued guideline, 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.  This podcast is part of the 2024 Update to the AHA/ACC HCM Guidelines: Expert Interpretation for Application to Practice grant initiative presented by ACCF and Med-IQ.